https://scholars.lib.ntu.edu.tw/handle/123456789/563375
標題: | N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients | 作者: | Hsu S.-P. CHIH-KANG CHIANG SHAO-YU YANG Chien C.-T. |
公開日期: | 2010 | 卷: | 116 | 期: | 3 | 起(迄)頁: | c207-c216 | 來源出版物: | Nephron - Clinical Practice | 摘要: | Background/Aims: To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients. Methods: Of the eligible patients (n = 325) in an outpatient HD unit, 49 received NAC 200 mg orally thrice a day during the first 3 months, while the other 276 patients not receiving NAC were observed. Results: During the 4-month study, 11 patients receiving NAC withdrew but had no severe adverse effects, while 49 patients not receiving NAC had negative confounding events. Thus only the data of the remaining patients, 38 taking NAC and 227 not taking NAC, were analyzed for efficacy. The demographic and laboratory data of both groups were similar at baseline. When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found to be a significant predictor of positive outcomes in uremic anemia. Conclusions: Oral NAC supplementation may be a promising therapy for uremic anemia and oxidative stress in HD patients. Copyright ? 2010 S. Karger AG, Basel. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77954184657&doi=10.1159%2f000317201&partnerID=40&md5=9040c0e8fb98a221ab865da86955f32e https://scholars.lib.ntu.edu.tw/handle/123456789/563375 |
ISSN: | 1660-2110 | DOI: | 10.1159/000317201 | SDG/關鍵字: | 8 isoprostane; acetylcysteine; flutafin; oxidized low density lipoprotein; unclassified drug; adult; aged; anemia; article; chronic glomerulonephritis; clinical trial; controlled clinical trial; controlled study; diabetic nephropathy; drug effect; drug efficacy; drug hypersensitivity; fatty acid blood level; female; hematocrit; hemodialysis patient; human; kidney failure; lipoprotein blood level; major clinical study; male; oxidative stress; priority journal; uremia; Acetylcysteine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antioxidants; Case-Control Studies; Chlorides; Dinoprost; Erythropoietin; Female; Ferric Compounds; Hematocrit; Humans; Kidney Failure, Chronic; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Recombinant Proteins; Renal Dialysis |
顯示於: | 毒理學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。